Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Anticancer Research|April 1, 2009
Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experienceDimitrios Pectasides, Eirini Pectasides, George Papaxoinis, et al.
Cancer Genomics & Proteomics|April 30, 2020
Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant ChemoradiotherapyEirini Pectasides, Ioannis Chatzidakis, Vassiliki Kotoula, et al.
Plos One|January 30, 2014
A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferonPetr Pancoska, John M Kirkwood, Spyros Bouros, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 16, 2016
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF InhibitionDouglas B Johnson, Eirini Pectasides, Emily Feld, et al.
Plos One|October 29, 2014
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsYong Sang Hong, Jihun Kim, Eirini Pectasides, et al.
Journal of Translational Medicine|November 4, 2010
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trialHelen Gogas, Urania Dafni, Henry Koon, et al.
Nature Communications|January 7, 2017
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinomaJin Zhou, Zhong Wu, Gabrielle Wong, et al.
The Journal of Clinical Investigation|November 18, 2014
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinomaJihun Kim, Cameron Fox, Shouyong Peng, et al.
ESMO Open|June 25, 2019
Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancerElena Fountzilas, Vassiliki Kotoula, George Pentheroudakis, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survivalLeonie K de Klerk, Anuj K Patel, Sarah Derks, et al.
Pageof 4